The world of online prediction markets is set to get even more unpredictable as Kalshi prepares to launch a pilot programme allowing users to bet on the outcomes of drug trials and regulatory decisions made by the US Food and Drug Administration (FDA). According to its CEO, Tarek Mansour, this innovative move aims to bring much-needed transparency to an often opaque process, providing a public probability that reflects the evidence rather than the trial sponsor's preferred narrative.
The initiative, in collaboration with artificial intelligence firm AppliedXL, hopes to make vital data more accessible to those who need it most – patients and clinicians. By surfacing this information responsibly, Kalshi is committed to compliance and long-term sustainability. But concerns have been raised about potential market manipulation and insider trading, as seen in recent high-profile cases involving federal regulators and politicians.
Despite these risks, Kalshi claims it will implement robust safeguards to prevent such issues within its new drug trial markets. These measures include requiring employment verification to deter insider trading, a system already in place for other markets on the platform. Contracts will only be listed after patient enrolment has concluded, aiming to prevent interference with recruitment or physician referrals.
A 44-page white paper detailing the future of drug development prediction markets features insights from healthcare industry leaders, including Anne Wojcicki, founder of 23andMe. She highlights the complex and often difficult-to-understand nature of clinical trials for most individuals, suggesting that an open and transparent dataset on trial probabilities could be empowering for patients seeking information.
This move comes as Kalshi continues to experience rapid growth, with a trading volume of £790 million earlier this year and over 5 million monthly users. The platform has reportedly explored offering contracts on flight cancellations, but paused the endeavour following concerns about potential user-driven disruptions.